Vanguard Group's Ownership in Kiniksa Pharmaceuticals

The Vanguard Group, Inc. has filed an amendment to its Schedule 13G, reporting ownership of 3,063,135 shares of common stock in Kiniksa Pharmaceuticals International Plc, representing 7.04% of the company's outstanding shares. The filing indicates that Vanguard holds these shares on behalf of its clients, including investment companies and managed accounts. The shares are held in the ordinary course of business and not for the purpose of influencing the control of the issuer. The filing also confirms that no single client owns more than 5% of the securities. The amendment was filed on October 31, 2025, and the reported ownership is as of September 30, 2025.